Jump to content
RemedySpot.com

Direct-Acting Antivirals in Treatment-Experienced HCV Patients

Rate this topic


Guest guest

Recommended Posts

CME/CE-Certified Module

September 9, 2011

Direct-Acting Antivirals in Treatment-Experienced HCV Patients

In this chapter from CCO's Annual Update 2011, Ira M. son, MD, reviews the data from povotal studies and discusses optimal use of protease inhibitor therapy in treatment-experienced individuals with genotype 1 HCV infection.

Topics covered include:

New Standard of Care in HCV Therapy

Overview of Lessons Learned From Phase II Trials of Boceprevir and Telaprevir

Overview of Phase III Trials of Boceprevir and Telaprevir in Treatment-Experienced Patients With Genotype 1 HCV

RESPOND-2: Phase III Trial of Boceprevir in Treatment-Experienced Patients With Genotype 1 HCV

REALIZE: Phase III Trial of Telaprevir in Treatment-Experienced Patient With Genotype 1 HCV

HCV Drug Resistance in Treatment-Experienced Patients Failing Protease Inhibitors

Conceptual Approach to Treating Previous Treatment Failures

HIV and Hepatitis C Annual Update 2011

http://clinicaloptions.com/Hepatitis/Annual%20Updates/2011%20Annual%20Update.aspx

Hepatitis Slide Library

Review hundreds of slidesets featuring the latest hepatitis

treatment data. Then download PowerPoint files for use in your own noncommercial talks. Click here to start.

HCV Treatment

FIND THE ANSWERS AT INPRACTICE.COM

Physicians: Jointly sponsored by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC.

Nurses: Annenberg Center for Health Sciences is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

Pharmacists: The Annenberg Center for Health Sciences at Eisenhower is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Release date: August 18, 2011Expiration date: August 17, 2012

Supported by educational grants from Abbott Laboratories, Gilead Sciences, Merck & Co, Tibotec, and Vertex.

Topics

Fibrosis and Cirrhosis

HIV Coinfection

HBV

Nash, ALD, etc

HCV

Other Hepatitis Viruses

Hepatocellular Carcinoma

Transplantation

Resources

Live Events

Expert Viewpoints

Bookstore

Slideset Downloads

Interactive Tools

Webcasts

Podcasts

Guidelines

Conference Coverage

CME Programs

Slidesets

Cases

Live Events

Bookstore

Resources

Site Map

RSS

Contact Us

Help

Site Requirements

Terms of Use

Privacy Policy

HIVSite Tour

International Editions

To ensure you receive Clinical Care Options educational materials by email,

please add info@... to your contacts or address book.

Not a member yet? Click here

Link to comment
Share on other sites

Join the conversation

You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.

Guest
Reply to this topic...

×   Pasted as rich text.   Paste as plain text instead

  Only 75 emoji are allowed.

×   Your link has been automatically embedded.   Display as a link instead

×   Your previous content has been restored.   Clear editor

×   You cannot paste images directly. Upload or insert images from URL.

Loading...
×
×
  • Create New...